Peptides for Liver Health: Ovagen Bioregulator and Hepatoprotective Peptides

The liver performs over 500 distinct biological functions — from synthesizing proteins and clotting factors to metabolizing toxins, regulating blood glucose, producing bile for fat digestion, and storing glycogen. Liver disease, in its many forms (NAFLD, hepatitis, alcoholic liver disease, drug-induced liver injury), represents a failure of hepatocyte function and the progressive replacement of functional liver tissue with fibrotic scar. Conventional medicine has few effective treatments for early-to-moderate liver dysfunction beyond addressing the causative factor. Hepatoprotective peptides — particularly the Ovagen bioregulator and BPC-157 — offer a gland-restoring approach that addresses liver health at the cellular gene expression level.

Ovagen: The Liver Peptide Bioregulator

Ovagen (Hepatamine) is a peptide bioregulator complex derived from bovine liver tissue, developed by the St. Petersburg Institute of Bioregulation and Gerontology. The short peptides in Ovagen penetrate hepatocytes and act as epigenetic regulators, restoring the gene expression patterns of aging or dysfunctional liver cells toward the patterns characteristic of young, healthy hepatocytes.

Specifically, Ovagen activates genes involved in: oxidative phosphorylation and mitochondrial function in hepatocytes, phase I and phase II detoxification enzyme synthesis (P450 enzymes, glutathione S-transferases, UDP-glucuronosyltransferases), bile acid synthesis and conjugation, protein synthesis (albumin, clotting factors, acute phase proteins), and anti-inflammatory signaling within the liver parenchyma.

In animal models of hepatic aging and in clinical cohort studies from Russian practice, Ovagen administration reduces liver enzyme elevations (ALT, AST), improves liver synthetic function markers (albumin, prothrombin time), and enhances hepatocyte ultrastructural integrity on electron microscopy. It is available in capsule form for oral administration (5–10 mg daily) or as an injectable preparation.

Standard dosing: Ovagen capsules 5 mg twice daily for 30 days, repeated quarterly. For significant liver dysfunction, injectable Ovagen 10 mg subcutaneously daily for 10 days provides more direct bioavailability.

BPC-157: Hepatoprotection and Liver Repair

BPC-157 is derived from a protein found in human gastric juice and has documented hepatoprotective effects in multiple animal models. In acetaminophen-induced liver toxicity (the most common cause of acute liver failure), BPC-157 significantly reduces hepatic necrosis, lowers ALT/AST elevations, and accelerates hepatocyte regeneration. The mechanism involves activation of the Egr-1 transcription factor in liver tissue, which drives expression of growth factors supporting hepatocyte survival and proliferation.

BPC-157 also reduces portal hypertension in animal models of liver cirrhosis — a critical complication of advanced liver disease — through its effects on nitric oxide synthesis and vascular tone in the portal circulation. This hepatovascular protective mechanism is unique among peptide therapies.

For liver health applications: BPC-157 at 250–500 mcg orally twice daily (liquid solution or capsule) for 8–12 week cycles. This provides local GI-portal delivery to the liver via the portal venous system, making oral administration particularly relevant for liver targets.

Glutathione Peptides and Liver Detoxification

Glutathione (gamma-glutamyl-cysteinyl-glycine) is the liver's master antioxidant and detoxification cofactor. Hepatic glutathione depletion is a final common pathway in many forms of liver toxicity. While reduced glutathione itself is not absorbed intact orally, several peptide-based approaches support hepatic glutathione synthesis: N-acetylcysteine (NAC, the rate-limiting glutathione precursor), S-acetyl glutathione (which survives gastric acid), and liposomal glutathione.

NAC at 600 mg three times daily is standard of care for acetaminophen toxicity and has benefits for NAFLD, alcoholic liver disease, and general hepatoprotection. Combining NAC with Ovagen addresses both the glutathione depletion and the hepatocyte gene expression restoration dimensions of liver health.

Thymalin and Immune-Mediated Liver Inflammation

Many liver conditions — including autoimmune hepatitis, primary biliary cholangitis, and some viral hepatitis — involve dysregulated immune attacks on hepatic tissue. Thymalin's immunomodulatory effects (normalizing T-cell activity and natural killer cell function) may reduce the immune-mediated component of liver inflammation in these conditions. This is understudied specifically for autoimmune hepatitis but mechanistically plausible.

NAFLD Protocol: A Comprehensive Peptide Approach

Non-alcoholic fatty liver disease affects approximately 25% of the global adult population and ranges from simple steatosis to NASH and cirrhosis. A comprehensive peptide-supported NAFLD protocol: Ovagen 5 mg twice daily + BPC-157 500 mcg orally twice daily + NAC 600 mg three times daily, combined with dietary interventions (low-refined-carbohydrate diet, caloric deficit if overweight) and aerobic exercise. MOTS-c's AMPK-activating mechanism also directly reduces hepatic lipid accumulation and is a logical addition at 5–10 mg subcutaneously 3 times weekly.

FAQ

Can Ovagen reverse liver fibrosis? Liver fibrosis involves structural collagen deposition that is partially reversible in early stages but increasingly permanent in advanced cirrhosis. Ovagen supports hepatocyte function and anti-inflammatory gene expression but cannot directly dissolve established fibrous scar tissue. Early intervention provides the best outcomes.

Is BPC-157 safe with compromised liver function? BPC-157 has not been specifically studied in patients with Child-Pugh B or C liver disease. Its favorable safety profile and hepatoprotective mechanisms make it theoretically beneficial, but use in advanced liver disease requires physician supervision and monitoring of liver function tests.

How does Ovagen compare to milk thistle (silymarin) for liver health? Silymarin stabilizes hepatocyte membranes and has antioxidant properties — it is the most evidence-backed herbal hepatoprotectant. Ovagen works through a different mechanism (epigenetic gene expression restoration) rather than antioxidant membrane protection. They are complementary, not redundant, and many protocols use both.

Related Articles

• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It
• Best Peptide Stacks for Recovery, Fat Loss, and Longevity

Track your supplements in Optimize.